Drugs / eASC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01743222 | Jan → May 2012 | — | Tigenix S.A.U. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | eASC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01743222 ↗ |
| Modality | Cell therapy | “expanded allogeneic adipose-derived stem cells (eASCs)” NCT01743222 ↗ |
| Route | Other | “Intra lymph node injection of 2.5 millions of eASCs” NCT01743222 ↗ |